Trialant
Platform
Home
Studies
Other
Contact Us
Terms of Service
Privacy Policy
Toggle Sidebar
Studies
Study
JSON
Overview
Key facts that identify this study and show where it stands today.
Description
What the study is about and why it is being run, in the researchers' own words.
Conditions
The medical conditions and diseases this study investigates.
Interventions
The treatments and procedures being evaluated in this study.
Participation
Who can join this study and the criteria used to decide.
Design
How the study is designed and how its participant groups are organized.
Contacts
The people to reach with questions about this study or how to join it.
Locations
Where the study is run and whether each site is currently recruiting.
Collaborators
The organizations and people involved in this study.
Similar Studies
Other registered studies that closely resemble this one.
Workspace
Home
Studies
Collections
Views
Contact Us
Terms of Service
Privacy Policy
Sign up
NCT01569204
HD21 for Advanced Stages
NCT02661503
Unknown status
Interventional
Phase 3
Updated May 13, 2024
HD12 for Advanced Stages
NCT00265031
Completed
Interventional
Phase 3
Updated Jun 25, 2012
HD18 for Advanced Stages in Hodgkins Lymphoma
NCT00515554
Completed
Interventional
Phase 3
Updated Nov 13, 2020
Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma
NCT00284271
Completed
Interventional
Phase 2
Updated Jul 29, 2011
Risk Adapted Beacopp Regimen for Standard and High Risk Hodgkin Lymphoma
NCT00305149
Completed
Interventional
Not Applicable
Updated Mar 21, 2006
Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin Lymphoma
NCT06919679
Not yet recruiting
Interventional
Phase 2
Updated Apr 9, 2025
Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma | NCT01569204 | Trialant
Save
Share
Completed
Interventional
Phase 2
Updated Oct 29, 2018
Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma
ClinicalTrials.gov ID
NCT01569204
Lead Sponsor
University of Cologne
OTHER
Overall Status
Completed
Study Type
Interventional
Phase
Phase 2
Enrollment
100
Estimated
Last Update Posted
Oct 29, 2018
Actual
Start Date
Oct 2012
Primary Completion Date
Mar 2014
Actual
Completion Date
Dec 2017
Actual
Brief Summary
The Purpose of this trial is:
to determine complete response rate (CRR) after six cycles of chemotherapy
to determine complete remission rate (CR/CRr) as final treatment outcome after completion of treatment
Hodgkin Lymphoma
Etoposide
Cyclophosphamide
Doxorubicin
Prednisone
Procarbazine
Dexamethasone
Dacarbazine
Brentuximab Vedotin
Ages Eligible for Study
Adult (18-64)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Histologically proven classical Hodgkin lymphoma
First diagnosis, no previous treatment, age: 18-60 years
Stage IIB with large mediastinal mass and/or extranodal lesions, stage III or IV disease
Exclusion Criteria:
Composite lymphoma or nodular lymphocyte- predominant Hodgkin lymphoma (NLPHL)
Previous malignancy
Prior chemotherapy or radiation
Primary Purpose
Treatment
Allocation
Randomized
Interventional Model
Parallel Assignment
Masking
None (Open Label)
No central contacts
There are no central contacts for this study.
1st Dept. of Medicine, Cologne University Hospital
Cologne, Germany
Google Maps
Lead Sponsor
University of Cologne
OTHER